
Impact Biomedical Completes Merger; Zoar Shareholder Gains About 94% Control
The shares will stop trading under IBO and are expected to reappear as ZOAR on NYSE American on Nov. 18, with the Zoar shareholder holding about 94% of the new parent.
Impact Biomedical Inc. · NYSE · Pharmaceutical Preparations

The shares will stop trading under IBO and are expected to reappear as ZOAR on NYSE American on Nov. 18, with the Zoar shareholder holding about 94% of the new parent.
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 24, 2026 | DSS Inc. 10% owner | Sold | 156 | $7.06 | $1,101 |
| Sept. 23, 2026 | DSS Inc. 10% owner | Sold | 27 | $6.95 | $188 |
| Sept. 22, 2026 | DSS Inc. 10% owner | Sold | 723 | $0.55 | $398 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Completion of acquisition or disposition of assets · Delisting notice / failure to meet listing standard · Material modification of security holders' rights · Change in control · Departure/appointment of directors or officers · Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits
AI summary, unreviewedImpact BioMedical Inc. completes reverse merger into Cayman-incorporated PubCo, delists from NYSE American, and shareholders are left with a 4.80% stake
Submission of matters to a vote of security holders
AI summary, unreviewedImpact Biomedical Inc. stockholders approve Zoar merger agreement and director slate at November 13, 2026 special meeting